1. Scrip
  2. >>Business
  3. >>Deals

Astex Bags Another Cancer Deal With MSD, This Time For ‘Undruggable’ p53 Target

Gets $35m Upfront

 
• By Ayisha Sharma

The UK-based biotech will license its Pyramid platform to MSD to develop anticancer compounds targeting p53, a key transcription factor dubbed the ‘guardian of the genome’ that has proven highly complex and challenging to drug.  

guardian angel image
TP53 Has Been Described As The Guardian Of The Genome • Source: Shutterstock
Key Takeaways:

  • Astex could get up to $500m in milestones per program as well as tiered royalties on sales.

  • The p53 transcription factor is difficult to target because of its structure and specificity.

  • Astex believes its fragment-based approach could unlock understanding of mutated p53.

Astex Pharmaceuticals, Inc. has clinched its third oncology partnership with MSD with a focus on the notoriously difficult p53 transcription factor target for $35m upfront after two prior...

Under the terms of the deal, the pharma major will get access to Astex’s proprietary fragment-based drug discovery platform, Pyramid, to develop compounds targeting several forms of the p53protein. Astex...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.